Allovir Inc
For the period ended Jun 30, 2024. Filed Aug 9, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 9, 2024
KLRS$1.87-18.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | |||||||
|---|---|---|---|---|---|---|---|
| (in thousands, except share amounts) · Shares · Amount · Capital · Loss · Deficit · Equity | |||||||
| Balance at December 31, 2022 | 93,093,243 | $9 | $690,753 | $(468) | $(465,775) | $224,519 | |
| Stock-based compensation | — | — | 10,029 | — | — | 10,029 | |
| Issuance of common stock, upon vesting of restricted stock | 334,747 | — | — | — | — | — | |
| Unrealized gain on available-for-sale securities | — | — | — | 167 | — | 167 | |
| Net loss | — | — | — | — | (41,183) | (41,183) | |
| Balance at March 31, 2023 | 93,427,990 | $9 | $700,782 | $(301) | $(506,958) | $193,532 | |
| Stock-based compensation | — | — | 10,288 | — | — | 10,288 | |
| Issuance of common stock, upon vesting of restricted stock | 179,092 | — | — | — | — | - | |
| Purchase of common stock under the 2020 Employee Stock Purchase Plan | 108,936 | — | 315 | — | — | 315 | |
| Issuance of common stock in public offering, net of underwriting discounts, commissions and offering costs | 20,000,000 | 2 | 70,167 | — | — | 70,169 | |
| Unrealized gain on available-for-sale securities | 76 | 76 | |||||
| Net loss | — | — | — | — | (45,267) | (45,267) | |
| Balance at June 30, 2023 | 113,716,018 | $11 | $781,552 | $(225) | $(552,225) | $229,113 | |
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| (in thousands, except share amounts) | Shares | Amount | Capital | Loss | Deficit | Equity |
| Balance at December 31, 2023 | 114,148,991 | $11 | $802,025 | $(62) | $(656,193) | 145,781 |
| Stock-based compensation | — | — | 5,034 | — | — | 5,034 |
| Issuance of common stock, upon vesting of restricted stock | 732,774 | — | — | — | — | — |
| Unrealized loss on available-for-sale securities | — | — | — | (76) | — | (76) |
| Net loss | — | — | — | — | (30,299) | (30,299) |
| Balance at March 31, 2024 | 114,881,765 | $11 | $807,059 | $(138) | $(686,492) | $120,440 |
| Stock-based compensation | — | — | 5,908 | — | — | 5,908 |
| Issuance of common stock, upon vesting of restricted stock | 394,309 | — | — | — | — | — |
| Purchase of common stock under the 2020 Employee Stock Purchase Plan | 36,337 | — | 21 | — | — | 21 |
| Unrealized loss on available-for-sale securities | — | — | — | (1) | — | (1) |
| Net loss | — | — | — | — | (6,076) | (6,076) |
| Balance at June 30, 2024 | 115,312,411 | $11 | $812,988 | $(139) | $(692,568) | $120,292 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.